BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
Rhea-AI Summary
BioCardia (NASDAQ: BCDA) will present at the CSI Focus Devices in Heart Failure congress in Frankfurt, Germany.
Peter Altman, PhD, President and CEO, will deliver an invited presentation titled “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.” The session is on Friday, December 5, 2025, during the Myocardial structural therapies targeting the ventricles session from 10:30–11:30 CET.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BCDA declined 4.14%, reflecting a moderate negative market reaction. This price movement removed approximately $605K from the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BCDA was up 1.38% pre-news, while key biotech peers like PHGE (-5.77%) and BCTX (-8.84%) were down, pointing to more stock-specific than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Board change | Positive | +3.6% | New director elected as experienced industry leader replaces outgoing member. |
| Dec 01 | Conference participation | Neutral | -4.1% | Announcement of invited presentation at CSI Focus heart failure congress. |
| Nov 24 | Leadership hire | Positive | +0.7% | Appointment of VP of Quality with extensive regulatory experience. |
| Nov 12 | Earnings and update | Positive | -3.1% | Q3 results, financing, trial progress, and cash runway into Q2 2026. |
| Nov 10 | Clinical enrollment | Positive | -0.8% | First patient enrolled in Phase 3 CardiAMP HF II heart failure trial. |
Recent news has triggered mostly modest single-digit moves with a mix of aligned and divergent reactions, including occasional selloffs on operationally positive updates.
Over the last month, BioCardia issued multiple updates, from leadership changes and board refreshment to clinical and financial progress. A Q3 2025 update on Nov 12 detailed financing, Phase 3 CardiAMP HF II enrollment and cash runway, yet saw a -3.08% move. A Phase 3 enrollment milestone on Nov 10 and this same CSI Focus presentation headline on Dec 1 also saw mild pressure, while governance and leadership news on Nov 24 and Dec 3 were met with small gains.
Market Pulse Summary
This announcement highlights BioCardia’s invited presentation on intramyocardial cell therapy for ischemic heart failure with reduced ejection at the CSI Focus Devices in Heart Failure congress. It reinforces ongoing engagement with the heart failure community rather than signaling a new trial result or financing. Recent history shows modest price moves around governance, clinical, and earnings updates, so investors may watch for subsequent data, regulatory milestones, or partnership developments as clearer catalysts.
Key Terms
intramyocardial medical
ischemic medical
cardiac output medical
AI-generated analysis. Not financial advice.
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia’s President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.”
| Meeting: | CSI Focus– Devices therapies in Heart Failure (D-HF) |
| Day: | Friday, December 5th |
| Session: | Myocardial structural therapies targeting the ventricles |
| Time: | 10:30 - 11:30 CET |
CSI Focus D-HF provides a comprehensive overview of device-based therapy in heart failure, including advancements in ventricle restoration strategies, device-based strategies to improve cardiac output, monitoring systems, and other cutting edge technologies and emerging platforms in this new field. For more information see: https://www.csi-congress.org/dhf.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: https://www.BioCardia.com.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to our presentation to be made at CSI-Focus D-HF. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors,” and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact: Miranda Peto, Investor Relations Email: mpeto@BioCardia.com Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: investors@BioCardia.com Phone: 650-226-0120
FAQ
When will BioCardia (BCDA) present at CSI Focus Devices in Heart Failure?
What is the title of the BioCardia (BCDA) presentation at CSI Focus D-HF?
Who will present for BioCardia (BCDA) at the CSI Focus D-HF congress?
Which session will include BioCardia's (BCDA) presentation at CSI Focus D-HF?
Where can investors find more details about the CSI Focus Devices in Heart Failure program?
Does the BioCardia (BCDA) announcement indicate any new financial guidance or data?
